|Bid||141.90 x 1100|
|Ask||142.15 x 1100|
|Day's Range||140.78 - 146.23|
|52 Week Range||118.62 - 148.75|
|Beta (3Y Monthly)||0.31|
|PE Ratio (TTM)||249.54|
|Earnings Date||Jan 22, 2019|
|Forward Dividend & Yield||3.60 (2.47%)|
|1y Target Est||148.11|
The stock markets finally caught a bid ahead of Thanksgiving, hoping to give investors some sort of comfort going into the holidays. For those that can’t help but sneak a peek at their portfolios, here are our top stock trades to watch for Friday. Shares of Foot Locker (NYSE:FL) are bursting higher on Wednesday, jumping 14% after the company beat on earnings, revenue and comp-store sales expectations.
The stock market today closed off session highs after gapping up at the open, then paring gains. The Nasdaq outperformed as tech stocks rebounded.
A U.S. appeals court on Wednesday declined a request by Johnson & Johnson for a temporary restraining order blocking sales of generic versions of its blockbuster prostate cancer drug Zytiga from hitting the U.S. market. The U.S. Court of Appeals for the Federal Circuit said it would not block Mylan NV and other companies from selling copycat versions of Zytiga while J&J seeks emergency relief at the U.S. Supreme Court.
The decision could cost J&J millions of dollars in sales for one of its best-selling products, gutting the market for the brand-name version of the blockbuster cancer drug. J&J was down 3.1 percent to $141.93 at 1:34 p.m. in New York, after earlier falling as much as 3.9 percent. The U.S. Court of Appeals for the Federal Circuit twice this week rejected J&J’s request to prevent copycat versions from from being sold in the U.S. while the drugmaker appeals a trial judge’s ruling that invalidated a patent on the medicine.
Shares of Johnson & Johnson fell 3.3% in afternoon trade, enough to pace declines among its health care peers and among the Dow Jones Industrial Average's components, after reports that an appeals court ruled that J&J can't block sales of generic Zytiga while the company appeals the overturning of a Zytiga patent. In J&J's third-quarter ended Sept. 30, Zytiga sales rose 43.2% from a year ago to $958 million, making it the company's third-highest selling drug. Jennifer Taubert, worldwide chairman of pharmaceuticals at J&J, said in the company's post-earnings conference call with analysts while the company was "pleased" with Zytiga, "we're absolutely not dependent on it," according to a transcript provided by FactSet. The company said total pharmaceutical operational sales growth was 8.2%, but if Zytiga was removed, growth would have still been a "really strong" 6.6%. The stock has still gained 4.6% over the past three months, while the SPDR Health Care Select Sector ETF has slipped 1.7% and the Dow has lost 4.6%.
Mylan (MYL) recalls batches of blood pressure medicine in the United States. The company receives warning letter from the FDA for the manufacturing facility in Morgantown, WV.
In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts gave it a “hold” rating. The mean rating for Stryker stock is 1.97 with a target price of $187.32, implying an upside potential of 11.7% over Stryker’s closing price of $167.72 on November 19, 2018.
Strong operational performance and upward movements in Stryker (SYK) stock have kept investors interested in the stock in 2018. In this series, we’ll explore Stryker’s financials, segment performance, analysts’ views on the stock, and valuation metrics of the company.
For fiscal 2018 and 2019, Stryker’s gross margin is expected to come in at 66.29% and 66.45%, respectively, as compared with gross margins of 66.31% for fiscal 2017. In comparison, fiscal 2018 gross margins of peers Abbott Laboratories (ABT), Johnson & Johnson (JNJ), and Zimmer Biomet Holdings (ZBH) are expected at 59.29%, 70.43%, and 71.91%, respectively. Stryker incurred selling, general, and administrative expenses of $1.24 billion in the third quarter of 2018 as compared with $1.10 billion in the third quarter of 2017.
NEW YORK, NY / ACCESSWIRE / November 21, 2018 / U.S. markets plunged on Tuesday as FAANG (Facebooks, Amazon, Apple, Netflix and Google) stocks entered into bear market territory, pressuring the tech sector ...
It remains the most referenced guide to prosperity because of its moral force: Smith said the freest markets are led by an invisible hand benefiting everyone, not just the individuals and companies motivated by their own profit. American free enterprise is achieving the greatest growth in the developed world, posting annual gross domestic product gains since 2009. Within just eight years of the global financial crisis, the U.S. was the only non-emerging-market economy with record GDP.
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
The Nasdaq got smacked with its biggest single-session loss in more than three weeks and nearly faced a test of the psychologically important 7000 level.
On November 16, Merck’s (MRK) stock price closed at $76.06, which represents ~1.63% growth from its close of $74.84 on November 15. Merck’s stock price grew from $56.79 when the market opened on January 2 to $76.06 when the market closed on November 16, which representing ~34% year-to-date growth. On November 16, Merck hit its 52-week high of $76.25.
The broad market is correcting deeply for a second straight trading session, with the big S&P 500 gapping down to re-test the lows set in October -- during the worst month for stocks since 2011. Tuesday shares are managing to hold up much better than the broad market.
Most stocks have been thoroughly shaken and stirred since early October, and a long-overdue corrective move finally took shape. Not even the bluest of the blue chips have been immune. The Dow Jones Industrial Average still is off its record high from a couple months ago, and several Dow stocks still are vulnerable to more selling. The initial shellshock has started to fade, however, the smoke is clearing and some stocks are recovering. Smart investors are now weighing the impact and searching for opportunities. Some Dow Jones stocks may have more downside to dish out, but a handful of these iconic names are looking oversold, undervalued and ripe for a rebound sooner than later. Remember: Corporate earnings have never been better, and consumer confidence is as high as it's been in years. Clearly something is going right. Here's a look at five Dow stocks that may have more ground to give up before they hit bottom, and two industrial-average components that may already be buys at current prices. But a note: Most of these "stocks to sell" are merely in short-term trouble. A sizable pullback from any of them could ultimately turn into a buying opportunity. SEE ALSO: 12 Vulnerable Stocks to Watch on Market-Wide Weakness
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
continues to struggle with management issues and the shortfall in Apple orders drove it to a new recent low. With those two stocks under heavy pressure there weren't any buyers rushing to buy the other big-cap technology names. Retail, biotechnology, software, semiconductors and most all of the sectors that lead in a strong market were down Monday.
The major indices continue to see extreme selling pressure. Breadth is running about 1,750 gainers to 5,350 decliners and new 12-month lows are over 300. There is a steady diet of bad news and no immediate technical support until the lows of October are retested.
"PFE's oncology assets will make up 13% of its total 2018 sales, according to FactSet, and they will accelerate PFE's sales growth for the foreseeable future, but these drugs are underappreciated," Cantor Fitzgerald analyst Louise Chen wrote on Sunday. The cancer drug market is expected to accelerate quickly in the coming years, growing from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020, according to Allied Market Research.